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Abstract
Background and purpose: Current methods to diagnose neurodegenerative diseases are 
costly and invasive. Retinal neuroanatomy may be a biomarker for more neurodegenera-
tive processes and can be quantified in vivo using optical coherence tomography (OCT), 
which is inexpensive and noninvasive. We examined the association of neuroretinal mor-
phology with brain MRI image-derived phenotypes (IDPs) in a large cohort of healthy 
older people.
Methods: UK Biobank participants aged 40 to 69 years old underwent comprehen-
sive examinations including ophthalmic and brain imaging assessments. Macular retinal 
nerve fibre layer (mRNFL), macular ganglion cell-inner plexiform layer (mGCIPL), macular 
ganglion cell complex (mGCC) and total macular thicknesses were obtained from OCT. 
Magnetic resonance imaging (MRI) IDPs assessed included total brain, grey matter, white 
matter and hippocampal volume. Multivariable linear regression models were used to 
evaluate associations between retinal layers thickness and brain MRI IDPs, adjusting for 
demographic factors and vascular risk factors.
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INTRODUC TION
Neurodegenerative diseases are emerging as the foremost challenge 
for biomedical science in the 21st century. It has been estimated 
that 46 million people are living with dementia, and this number is 
expected to rise to 131 million by 2050 [1,2]. Prevalence of demen-
tia increases with age, affecting 11%, 32% and 82% of people aged 
over 65, 75 and 85 years, respectively [3]. Some projections suggest 
that, due to population aging, the prevalence of Alzheimer disease 
(AD), the most common form of dementia, may triple by 2050 [2,3]. 
Studies have reported age-related decreases in global and regional 
brain changes measured by magnetic resonance imaging (MRI) [4]. 
Brain volume declines with age at a rate of around 5% per decade 
after age 40, and the rate of decline accelerates after 70 years of 
age [5,6]. Brain MRI is accurate and sensitive in detecting structural 
variations in the brain, some of which are associated with neurode-
generation, but is relatively costly and time consuming [7]. Simpler, 
resource saving, reproducible biomarkers would offer the prospect 
of enabling earlier diagnosis of dementia.
The retina and optic nerve share their embryological origin with 
the brain, and are widely regarded as part of the central nervous sys-
tem [8]. Retinal microvasculature and neuronal components offer a 
unique window on tissues that are closely allied to intracranial struc-
tures [9]. Consequently, the eye is vulnerable to similar processes 
that are associated with neurodegenerative diseases [8]. Spectral-
domain optical coherence tomography (SD-OCT) is an in vivo im-
aging tool that allows noninvasive, high-resolution examination of 
retinal structure [10]. Automated segmentation techniques now 
make quantitative assessment of retinal sublayers a viable proposi-
tion [11]. This offers the prospect of retinal imaging contributing to 
the diagnosis and monitoring of diseases characterised by structural 
changes in the brain.
There is a well-recognised link between dementia and degenera-
tive changes in the retina and optic nerve [12]. Both histopathologi-
cal and clinical studies have shown that evidence of retinal ganglion 
cell degeneration in AD patients[13–16], but only the Rotterdam 
Study has evaluated whether retinal degeneration may be a marker 
for subclinical brain disease [17]. To date, most interest has focused 
on the thickness of the peripapillary retinal nerve fibre layer (pRNFL) 
as a potential biomarker for dementia [18]. Few studies have exam-
ined the relationship between retinal sublayer thickness and cere-
bral atrophy on MRI [17,19]. In this UK Biobank study, we aimed to 
investigate the association between inner retinal layer thicknesses 
and regional brain volumes in a healthy population to better under-
stand how accessible and affordable eye measurement may contrib-
ute as a biomarker for brain structure.
METHODS
Study population
UK Biobank is a very large community-based cohort of UK resi-
dents registered with the National Health Service and aged 40 to 
69 years at enrolment. Baseline examinations were carried out be-
tween 2006 and 2010 at 22 study assessment centres. The North 
West Multicentre Research Ethics Committee approved the study 
in accordance with the principles of the Declaration of Helsinki. The 
overall study protocol (http://www.ukbio bank.ac.uk/resou rces/) 
and protocols for individual tests (http://bioba nk.ctsu.ox.ac.uk/
cryst al/docs.cgi) are available online. In brief, participants answered 
a wide-ranging touch-screen questionnaire covering demographic, 
socioeconomic and lifestyle information. Physical measures in-
cluded blood pressure, height and weight. Body mass index (BMI) 
was defined as weight divided by height squared.
Ocular measurements
In late 2009, eye measurements were conducted in six assessment 
centres by trained staff following standard operating procedures; 
detailed methods have been published [20,21]. Visual acuity and 
preparation, review, or approval of the 
manuscript; nor in the decision to submit 
the manuscript for publication.
Results: A total of 2131 participants (mean age 55 years; 51% women) with both gradable 
OCT images and brain imaging assessments were included. In multivariable regression 
analysis, thinner mGCIPL, mGCC and total macular thickness were all significantly associ-
ated with smaller total brain (p < 0.001), grey matter and white matter volume (p < 0.01), 
and grey matter volume in the occipital pole (p < 0.05). Thinner mGCC and total macular 
thicknesses were associated with smaller hippocampal volume (p < 0.02). No association 
was found between mRNFL and the MRI IDPs.
Conclusions: Markers of retinal neurodegeneration are associated with smaller brain vol-
umes. Our findings suggest that retinal structure may be a biomarker providing informa-
tion about important brain structure in healthy older adults.
K E Y W O R D S
brain MRI markers, cognitive impairment, optical coherence tomography, retinal layers, retinal 
neurodegeneration
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intraocular pressure (IOP) were measured. Corneal-compensated 
IOP (IOPcc) was measured with the ocular response analyser 
(Reichert, Philadelphia, PA, USA) to examine the influence that 
corneal biomechanical characteristics might have on IOP measures 
[20,22].
Spectral-domain optical coherence tomography
Spectral-domain optical coherence tomography imaging was per-
formed using the Topcon 3D OCT-1000 Mk2 (Topcon, Tokyo, Japan). 
Image acquisition was performed under mesopic conditions, without 
pupillary dilation using the three-dimensional macular volume scan 
(512 horizontal A scans per B scan; 128 B scans in a 6 × 6 mm2 ras-
ter pattern). The Topcon Advanced Boundary Segmentation (TABS) 
algorithm was used for automated segmentation [23]. Retinal lay-
ers were labelled as macular retinal nerve fibre layer (mRNFL), 
macular ganglion cell-inner plexiform layer (mGCIPL), macular gan-
glion cell complex (mGCC) and total macular thickness. Thickness 
of the mGCIPL includes the macular ganglion cell layer (mGCL) and 
macular inner plexiform layer (mIPL), whereas mGCC includes both 
mRNFL and mGCIPL. We followed the Advised Protocol for OCT 
Study Terminology and Elements (APOSTEL) guidelines, except 
with respect to the total macular thickness, which we define as the 
thickness from the inner limiting membrane to the retinal pigment 
epithelium [24]. mRNFL is composed of axons of the retinal ganglion 
cell, whereas mGCL is composed of ganglion cell bodies, and mIPL 
is composed of retinal ganglion cell dendrites. We used the average 
thickness of the retinal layers in the macula across nine retinal sub-
fields in a 6-mm-diameter circle centred at the true fovea location, 
as derived from the ETDRS (Early Treatment Diabetic Retinopathy 
Study) [25]. We have added the prefix “m” to the sublayer abbrevia-
tions to denote as macular measures, as some SD-OCT metrics can 
be derived from images centred on the optic disc.
MRI Brain Image-Derived Phenotypes (IDPs)
MRI imaging protocols were designed by the UK Biobank Imaging 
Working Group (http://www.ukbio bank.ac.uk/exper t-worki ng-
groups). Details of the image acquisition and processing are available 
on the UK Biobank website in the brain scan protocol (http://bioba 
nk.ctsu.ox.ac.uk/cryst al/refer.cgi?id=2367) and brain imaging docu-
mentation (http://bioba nk.ctsu.ox.ac.uk/cryst al/docs/brain_mri.
pdf). Briefly, brain imaging was carried out using a single standard 
Siemens Skyra 3T scanner with a 32-channel radio-frequency (RF) 
receive head coil. Key acquisition parameters for each modality are 
summarised in a prior publication [26]. The T1-weighted scans were 
acquired using three-dimensional magnetization-prepared rapid 
gradient-echo (MPRAGE) (resolution 1 mm3 isotropic voxels) and 
analysed with the Functional Magnetic Resonance Imaging of the 
Brain (FMRIB) Software Library (FSL) (http://fsl.fmrib.ox.ac.uk/fsl). 
Further details on MRI acquisition and analysis have been reported 
elsewhere [26,27]. Brain images were analysed to derive multiple 
distinct individual measures of brain structure and function, known 
as brain image-derived phenotypes (IDPs) [26]. Total brain volume 
was defined as the sum of grey matter volume and white matter 
volume. Grey matter volume in the frontal, temporal and occipital 
poles and hippocampal volume were averaged from the right and left 
volumes. Total brain, grey matter and white matter volumes were 
normalised for head size. Grey-matter volume in the frontal, tempo-
ral and occipital poles (V1/V2) and hippocampus volume were nor-
malised for head size by multiplying the individual brain IDPs by the 
volumetric scaling from T1 head image to standard space. Brain IDPs 
were normalised for head size, which is a close proxy for intracranial 
volume [28]. Normalised brain IDPs were termed as total brain, grey 
matter, white matter and hippocampal normalised.
Inclusion and exclusion criteria
To ensure the accuracy of retinal thickness assessment, we have ex-
cluded OCT scans of poor quality consistent with the OSCAR IB’’ 
[(O)= obvious problems including violation of the protocol; (S) poor 
signal strength defined as ,15 dB; (C) wrong centration of scan; (A) al-
gorithm failure; (R) retinal pathology other than MS related; (I) illumi-
nation; and (B) beam placement]. (OSCAR-IB) criteria [29]. In general, 
the OSCAR-IB criteria requires good quality OCT scans and signal 
strength with no visible retinal pathology. Among those with SD-
OCT data, we excluded participants who withdrew their consent, 
had poor SD-OCT signal strength, had an image quality score <45, 
had poor centration certainty or had poor segmentation certainty 
using TABS software [30,31]. Participants with the following condi-
tions were also excluded from the study: visual acuity worse than 
0.5 logarithm of the minimum angle of resolution (logMAR) (approxi-
mately 6/18 on Snellen chart), IOPcc of <6 mm Hg or >24 mm Hg [32], 
self-reported ocular disorders or diseases, self-reported diabetes or 
self-reported neurodegenerative disease. This group of participants 
were excluded from the study because of the well-recognised im-
pact these conditions have on retinal layer thickness [33–35].
Statistical analysis
The present analysis was based on cross-sectional data. For this 
analysis, if both eyes of a patient were eligible for inclusion, one eye 
was randomly selected using Stata software (version 16; StataCorp, 
College Station, TX, USA). The z scores of the four retinal sublayer 
thickness and brain MRI markers were calculated by subtracting 
the mean value from the value of the observation and dividing by 
the standard deviation. We examined the association of retinal sub-
layer thickness (explanatory or independent variable) with brain MRI 
markers (dependent variable) using two multivariable linear regres-
sion models: Model 1 adjusted for age, age squared and sex; and 
Model 2 additionally adjusted for race, education, BMI, mean arte-
rial blood pressure and smoking status. Cardiovascular risk factors 
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including BMI, mean arterial blood pressure and smoking status 
were adjusted for in the multivariable models in view of their rela-
tionship with brain MRI markers [36–38] and retinal layers[39].We 
minimised the effect of age on cerebral atrophy by adjusting for age 
and age squared. In sensitivity analysis, we additionally adjusted for 
total grey matter normalised when the outcome was hippocampal 
normalised. The β coefficients represent standardised mean differ-
ence in z scores of total brain, grey or white matter and hippocampal 
normalised per SD decrease in retinal sublayer thickness. We ap-
plied linear transformation and have used z scores as standardizing 
scores to facilitate the interpretation of the value of the individual 
brain IDPs.
RESULTS
There were 7187 participants with data on SD-OCT macular imag-
ing and brain MRI scans. Of these, 4105 people with visual acuity 
worse than 0.5 logMAR (equivalent to 6/18 on Snellen chart), IOPcc 
of <6 mm Hg or >24 mm Hg, self-reported eye diseases, diabetes 
and neurological disorders were excluded. Of the remaining 3082, 
773 participants with poor SD-OCT image quality were excluded, 
and 178 participants were further excluded due to missing data for 
covariables. There were complete data (age, sex, race, education, 
BMI, mean arterial blood pressure and smoking) for 2131 of these 
participants (Figure 1).
The characteristics of the study population are shown in Table 1. 
The mean age was 54.6 years (SD = 7.4), and 1084 (51%) of the par-
ticipants were female. The overall mean (SD) of the different ret-
inal layers was: mRNFL (29.2 µm [SD, 4.6 µm]), mGCIPL (74.1 µm 
[5.9 µm]), mGCC (103.3 µm [8.0 µm]) and total macular thickness 
(278.7 µm [12.7 µm]). Table 2 shows the multivariable analysis of 
retinal sublayer thickness with total brain, grey matter, white matter 
and hippocampal normalised after adjusting for age, age squared and 
sex. In general, thinner mRNFL, mGCIPL, mGCC and total macular 
thickness were all significantly associated with smaller total brain, 
grey matter and white matter normalised (except the association be-
tween mRNFL and total white matter normalised). Reduced mRNFL, 
F I G U R E  1  Flowchart of participants included in the study. BMI, body mass index; IOPcc, corneal-compensated intraocular pressure; 
logMAR, logarithm of the minimum angle of resolution; MRI, magnetic resonance imaging; SD-OCT, spectral-domain optical coherence 
tomography; VA, visual acuity.
Total number of participants 
with available SD-OCT and 
brain MRI measures 
(N=7,187)
Excluded
VA worse than 0.5 logMAR, IOPcc <6mmHg or >24mmHg, 
self-reported eye diseases, self-reported diabetes and self-




Poor SD-OCT signal strength, image quality score <45, 
poor centration certainty, poor segmentation certainty and 




Age, sex, race, education, BMI, mean arterial blood 
pressure, smoking status  
(N=178)
2,131 participants with 
complete data for examining 
retinal layers as outcomes 
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mGCC and total macular thickness were associated with smaller 
hippocampal normalised, but the associations were not signifi-
cant (p > 0.05) when we additionally adjusted for total grey matter 
normalised.
Table 3 shows the multivariable analysis of retinal sublayer 
thickness with MRI IDPs after adjusting for age, age squared, sex, 
race, education, BMI, mean arterial blood pressure and smoking 
status. Thinner mGCIPL, mGCC, and total macular thickness were 
all significantly associated with smaller total brain normalised, stan-
dardised mean difference (95% CI) per SD decrease in retinal sub-
layer thickness, respectively: −0.08 (95% confidence interval [CI]: 
−0.12, −0.05; p < 0.001), −0.08 (95% CI: −0.12, −0.04; p < 0.001) and 
−0.08 (95% CI: −0.11, −0.04; p < 0.001). Reduced mGCIPL, mGCC 
and total macular thickness were significantly associated with grey 
matter normalised, standardised mean difference (95% CI) per SD 
decrease in retinal sublayer thickness, respectively: −0.04 (95% CI: 
−0.08, −0.01; p = 0.009), −0.05 (95% CI: −0.08, −0.02; p = 0.003) and 
−0.06 (95% CI: −0.09, −0.02; p = 0.001). Thinner mGCIPL, mGCC and 
total macular thickness were also significantly associated with white 
matter normalised, standardised mean difference (95% CI) per SD 
decrease in retinal sublayer thickness, respectively: −0.09 (95% CI: 
−0.13, −0.05; p < 0.001), −0.08 (95% CI: −0.12, −0.04; p < 0.001) and 
−0.07 (95% CI: −0.11, −0.03; p = 0.001). Reduced mGCC thickness 
was associated with smaller grey matter normalised in the frontal 
pole, standardised mean difference (95% CI) per SD decrease in 
mGCC thickness: −0.04 (95% CI: −0.08, −0.002; p = 0.038). Thinner 
mGCIPL, mGCC and total macular thickness were associated with 
smaller grey matter normalised in the occipital pole, standardised 
mean difference (95% CI) per SD decrease in retinal sublayer thick-
ness, respectively: −0.06 (95% CI: −0.10, −0.02; p = 0.003), −0.06 
(95% CI: −0.10, −0.02; p = 0.006) and −0.05 (95% CI: −0.09, −0.008; 
p = 0.020). Thinner mGCC and total macular thickness were asso-
ciated with smaller hippocampal normalised, standardised mean 
difference (95% CI) per SD decrease in retinal sublayer thickness, re-
spectively: −0.05 (95% CI: −0.09, −0.008; p = 0.018), and −0.05 (95% 
CI: −0.09, −0.01; p = 0.010) but were no longer significant (p > 0.05) 
when we additionally adjusted for total grey matter normalised. 
There were no significant associations between mRNFL thickness 
and the brain MRI measures. Additional adjustment for IOPcc, the 
sole modifiable risk factor for glaucoma, did not meaningfully change 
the effect estimates between retinal sublayer thicknesses and brain 
MRI markers.
DISCUSSION
In this study, we identified that thinner mGCIPL, mGCC and total 
macular thickness were associated with smaller total brain normal-
ised, grey and white matter normalised, and grey matter normalised 
in the occipital pole. Reduced mGCC was associated with smaller 
grey matter normalised in the frontal pole, whereas mRNFL thick-
ness was not associated with the MRI IDPs. This suggests that reti-
nal thickness measures provide not only useful information on brain 
function, but also on anatomically relevant brain structures.
Cognitive impairment in dementia is characterised by cerebral 
atrophy. Our study has shown that thinner mGCIPL, mGCC and total 
macular thicknesses were associated with smaller total brain, grey 
and white matter normalised. In addition, because of the age-related 
effects on cerebral atrophy, we adjusted for age and age squared 
to minimise the possibility of confounding by age. Our data suggest 
that neuronal damage may occur in the retina and throughout the 
brain. Our result was consistent with a report from the Rotterdam 
Study Group that reported thinner inner retinal layers were asso-
ciated with total brain, grey and white matter volumes [17]. Our 
findings showed that thinner mGCIPL, mGCC and total macular 
thicknesses were associated with reduced grey-matter normalised 
in the occipital pole. It is well known that atrophy of the occipital 
lobe, particularly V1/V2, is known to cause inner retinal layer atro-
phy by retrograde transsynaptic axonal degeneration. In agreement 
with our findings, Ong et al. reported that thinner mGCIPL was as-
sociated with smaller grey matter volume in the occipital lobe [19]. 
These data are also consistent with a number of studies in control 
subjects and patients with multiple sclerosis [40–42]. The associa-
tion of inner retinal layer atrophy was strongest for V1 and V2 using 
validated segmentation software. Taken together, the published 
data suggest a strong association between pathology and atrophy 
in these areas. The question becomes more complex for impaired 
higher visual function. AD pathology of the lateral occipital cortices 
and parietal lobes are not known to be associated with atrophy of 
TA B L E  1  Characteristics of the study population (n = 2131)
Characteristic N Mean ± SDa  %













Degree and above 978 45.9





Mean arterial blood 
pressure, mm Hg
2131 100.7 ± 12.1
aMean (SD) for continuous variables and percentages for categorical 
variables. 
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inner retinal layers in the macula. Therefore, a limitation of the study 
is that impaired visual perception in AD is unlikely to be captured by 
atrophy of the mGCC/mGCIPL.
Hippocampal atrophy is a major feature of AD and a diagnos-
tic marker for AD at the mild cognitive impairment stage [43]. 
Histological studies have shown considerable neuronal loss in the 
hippocampus at onset of symptoms [44]. In agreement with histo-
logical findings, longitudinal studies reported accelerated hippo-
campal volume loss in AD [45–48] and mild cognitive impairment 
(MCI) [49,50]. In addition to smaller hippocampal volumes observed 
in patients with cognitive impairment, evidence also suggests that 
the inhibition of adult hippocampal neurogenesis leads to memory 
impairments [51,52], whereas enhancing neurogenesis improves 
memory performance [53,54]. Given that hippocampal atrophy is a 
prominent feature of AD and MCI, our findings that, in an adult popu-
lation, thinner mGCC and total macular thicknesses were associated 
with smaller hippocampal normalised, suggests that common mech-
anisms may lead to hippocampal and retinal atrophy. Additionally, 
we examined the association between total macular thickness and 
brain MRI, and observed that thinner total macular thickness was 
associated with smaller brain MRI structural measures. Because the 
presence of imaging artefacts may decrease the accuracy of spe-
cific retinal thickness measurements, measurement of total macu-
lar thickness is more accurate compared to specific sublayer retinal 
thickness [55]. In line with our findings, the Rotterdam Study re-
ported that thinner inner retinal layers were associated with smaller 
hippocampal volumes, although grey volume was not adjusted in the 
multivariable models [17].
Nonetheless, in a sensitivity analysis, we did not find an asso-
ciation between the inner retinal layers or total macular thickness 
and hippocampal normalised after the additional adjustment of total 
grey matter volume. This suggests that, at least among the healthy 
UK Biobank participants, the relationship between thinner retinal 
measures and smaller hippocampal volumes is explicable as a con-
sequence of smaller total grey matter volume [56], which could be 
a consequence of either global neurodegeneration or differences in 
neurodevelopment. Measurement of relative rates of volume loss 
over time in the same individuals will disambiguate this question.
Previous studies by Blanks et al. [13] and Hinton et al. [14] re-
ported that patients with AD have apparent histological signs of 
retinal ganglion cell and mRNFL loss compared to controls, consis-
tent with accelerated neurodegeneration. Clinic-based studies have 
demonstrated that patients with AD or mild cognitive impairment 
have reduced pRNFL [34], mGCIPL [57], mGCC [58] and total mac-
ular thickness [59,60] compared to controls. AD is associated with 
cerebral atrophy on high-resolution MRI [43]. Although our findings 
suggest that inner retinal and total macular thickness measurements 
may be a biomarker for brain structure, further work would be 
needed to examine the utility of retinal parameters as a diagnostic 
or screening tool for diseases that affect brain structure.
We did not identify significant associations between mRNFL 
thickness and brain MRI structural measures. However, pRNFL was 
not measured in our study. Thinner pRNFL was associated with grey 
matter volume in the temporal lobe in a Singapore study [19] and 
thinner pRNFL was associated with smaller grey matter and white 
matter volumes in the Rotterdam Study [17]. As the mRNFL axon 
bundles that arise from retinal ganglion cells converge toward the 
optic disc, mRNFL in the macula is much thinner compared to pRNFL 
(and vice versa for mGCIPL) [61], which may explain the lack of as-
sociation between mRNFL thickness and brain MRI measures in our 
study. In addition, reduction in dendritic complexity and area occurs 
prior to retinal ganglion cell death and loss [62], which suggests that 
mGCIPL may be more sensitive at detecting neurodegenerative 
damage compared to mRNFL.
The strengths of our study include its large sample, the quan-
titative assessment of retinal sublayers on SD-OCT and the brain 
structures on MRI. Limitations of the study include the UK Biobank 
is a volunteer cohort, and participants are likely to be healthier than 
the general population. In addition, a large number of the partici-
pants with eye data did not yet have data on brain structural MRI 
measures. The self-reported nature of glaucoma, ocular disorders, 
diabetes or neurodegenerative disease also could result in misclassi-
fication bias. However, as both the retinal structures measured with 
SD-OCT and brain MRI structures are objective measures, the lat-
ter is more likely to be nondifferential misclassification and bias the 
effect estimates toward the null. The cross-sectional design of our 
study limits the ability to determine the cause and effect of the rela-
tionship between retinal structures and brain MRI markers. Among 
healthy older adults (i.e., our cohort), there is extreme variability in 
the relationship between hippocampal size and memory [63]. Our 
study may not be able to identify pathological trends, but rather pro-
vides information on the trends to be expected in a healthy, older 
population.
In conclusion, thinner mGCIPL, mGCC and total macular thick-
ness are associated with smaller total brain, grey matter and white 
matter normalised in a cohort of healthy adults. Our findings sup-
port the concept that retinal layer thickness is a biomarker for pro-
cesses affecting central nervous system structure. Further research 
examining the utility of retinal measures as an affordable, noninva-
sive investigation of neurological conditions is warranted.
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